Anti-CD19 chimeric antigen receptor T cell therapy(Innovative Cellular)

抗CD19嵌合抗原受体 T 细胞疗法(上海斯丹赛)

Report date: 2022/04/11 17:00:15

Base Information

Drug NameAnti-CD19 chimeric antigen receptor T cell therapy(Innovative Cellular)
Drug Alias NameICTCAR-003
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesInnovative Cellular Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInnovative Cellular Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A